Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1

Conditions

Polycystic Ovary Syndrome 1Overweight 1Obesity 1Insulin Resistance 1Hyperandrogenism 1

Interventions

Paclitaxel 336pembrolizumab 332Carboplatin 329Cisplatin 276Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 210Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 117Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84Bortezomib 77durvalumab 76Azacitidine 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Has results × licogliflozin × Clear all
NCT03152591 2021-01-05

PCOS

Novartis

Phase 2 Completed
29 enrolled 24 charts
Other

Insulin Resistance, Obesity, Polycystic Ovary Syndrome, Hyperandrogenism, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡